European Patent Office Grants Biomoda Patent
01.24.2012 — 8:00 am
The European Patent Office (EPO) has granted Biomoda, Inc.’s patent application for using our proprietary CyPath® technology to detect cancer and pre-cancerous cells in body fluid and tissue samples.
Titled “Composition and Methods for Detecting Pre-Cancerous Conditions In Cell And Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenol) Porphine,” EPO patent 1364044 is similar to Biomoda’s US patent 6,838,248, which was issued in 2005. Foreign equivalents are also effective in Canada, Mexico, Japan and Australia.
The EPO patent strengthens Biomoda’s existing European patent portfolio and the company’s entry into the market, where the potential demand for an inexpensive, noninvasive diagnostic assay for early-stage lung cancer is estimated to be five times the US market. According to the World Health Organization, there are 215 million current smokers in the European Union and tobacco is the leading contributor to the disease burden in more than half the EU countries.
The European Patent Office cooperates with the U.S. Patent and Trademark Office and the Japan Patent Office as part of a cooperative program established to improve the efficiency of the global patent system.
We welcome questions from investors. Please submit questions to email@example.com.
Biomoda is focused on the development of in vitro tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.